Please login to the form below

Not currently logged in

Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund

Around 3,200 women in England could be eligible for treatment


Pfizer’s Ibrance has been approved by the National Institute for Health and Care Excellence (NICE) in England through its Cancer Drugs Fund as a second-line treatment for advanced breast cancer.

Ibrance (palbociclib), in combination with fluvestrant has been approved for use via the Cancer Drugs Fund in women with previously treated, HR positive and HER2 negative metastatic breast cancer.

According to a statement released by Pfizer, there are approximately 3,200 women in England living with this specific type of cancer who could now be eligible for the treatment.

Pfizer’s drug can be used to treat patients who have already had earlier rounds of hormone therapy for their advanced disease, and is an important additional treatment for women who may have limited options.

“This outcome marks a significant milestone for the secondary breast cancer community. We know how important it is for women to have access to treatment options that can delay the progression of their disease and help them live a normal life for longer, and we are delighted that through the CDF this option will be available,” said Olivia Ashman, oncology medical director, Pfizer UK.

The CDK 4/6 inhibitor is designed to halt tumour cell growth and delay progression, and is the first oncology therapy that increases the effect of aromatase inhibitors to do so.

It originally scored approval in the EU in November 2016, for the treatments of hormone receptor positive, HER-2 negative, locally advanced metastatic breast cancer.

NICE initially ruled that Ibrance was not a cost-effective use of NHS resources, and said that while Ibrance has been shown to stall disease progression for an average of 10 months more than traditional treatment standard, more clinical evidence was required to quantify overall survival improvement.

However, it then re-considered its decision after Pfizer submitted an ‘improved patient access scheme’, and approved Ibrance for the first-line treatment of advanced breast cancer on combination with an aromatase inhibitor in women with hormone receptor-positive, HER-2 negative tumours.

“This class of medicine remains one of the most important breakthroughs in breast cancer in the last two decades and palbociclib has been shown to slow tumour growth and maintain quality of life, both of which are incredibly important to women living with this type of breast cancer,” said Nicholas Turner, professor of molecular oncology at The Institute of Cancer Research, London and consultant medical oncologist at The Royal Marsden NHS Foundation Trust.

“Today’s news will be warmly welcomed by patients and doctors alike,” he added.

Article by
Lucy Parsons

28th November 2019

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
Senior Analytics Specialist joins Research Partnership...